The worldwide rapid rise in diabetes is a challenge for treatment as well as for diagnosis and monitoring. With the new test HbA1c net FS, DiaSys has introduced an innovative product with highest accuracy setting new standards for reliable results in diagnosing and monitoring diabetes. Based on enzymatic measurement Hba1c net FS ensures highest specificity without interferences by hemoglobin variants or other substances in blood as well as outstanding precision. In combination with the DiaSys analyzers, JCA-BioMajesty® BM 6010/C and respons®910, labs of every size can optimize their workflow for HbA1c due to the fully automated process including on-board hemolysis.
Besides this crucial product launch, other major achievements were made in time for DiaSys’ 25th anniversary. Under the trademark QDx DiaSys announced a point-of-care product line comprising test strips and devices for various diagnostic fields as cardiac, vitamin D, allergy, anemia, lipids and urinalysis. The recently founded subsidiary DiaSys USA introduced the respons®910VET as versatile solution for the veterinarian lab. Furthermore, respons®910UP was presented. The upgraded version of DiaSys’ analyzer for the small clinical lab offers improved handling and performance and lead to boosting sales establishing DiaSys as player in the systems market.
25 years of success as a mid-size company in the challenging and ever changing market of in-vitro diagnostics - DiaSys takes this opportunity to thank all employees, customers and partners for their contribution and confidence and looks forward to a common prospering future.
Exhibitor Data Sheet